MAP2K6

Across TCGA pan-cancer cohorts, MAP2K6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MAP2K6 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MAP2K6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAP2K6 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

LUAD, CCRCC, and GBM are the cancer types where MAP2K6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.762	1.000	.022	8	view →
CCRCC	OS	Tertile	All	1.000	0.733	.018	6	view →
GBM	OS	Tertile	All	0.653	0.436	.022	4	view →
LSCC	DFS	Quartile	All	1.000	0.902	.017	3	view →
PDAC	DFS	Median	All	0.423	0.224	.018	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MAP2K6–LUAD (DFS)

Open the LUAD breakdown →